{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:21:44Z","timestamp":1785410504382,"version":"3.56.0"},"reference-count":105,"publisher":"Hosokawa Powder Technology Foundation","issue":"0","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI141082"],"award-info":[{"award-number":["R01AI141082"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["KONA"],"published-print":{"date-parts":[[2026,1,10]]},"DOI":"10.14356\/kona.2026011","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T18:08:06Z","timestamp":1750442886000},"page":"141-154","source":"Crossref","is-referenced-by-count":1,"title":["Outstanding Contributions to Aerosol Pulmonary Drug Delivery"],"prefix":"10.14356","volume":"43","author":[{"given":"Anthony J.","family":"Hickey","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/052tfza37","id-type":"ROR","asserted-by":"publisher"}],"name":"Technology Advancement and Commercialization, RTI International, USA"},{"id":[{"id":"https:\/\/ror.org\/0130frc33","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9204-5155","authenticated-orcid":false,"given":"Erik S.","family":"Pena","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/052tfza37","id-type":"ROR","asserted-by":"publisher"}],"name":"Technology Advancement and Commercialization, RTI International, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0114-0550","authenticated-orcid":false,"given":"Sara E.","family":"Maloney Norcross","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/052tfza37","id-type":"ROR","asserted-by":"publisher"}],"name":"Technology Advancement and Commercialization, RTI International, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5463","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Almgren M., Edwards K., Karlsson G., Cryo transmission electron microscopy of liposomes and related structures, Colloids and Surfaces A: Physicochemical and Engineering Aspects, 174 (2000) 3\u201321. https:\/\/doi.org\/10.1016\/S0927-7757(00)00516-1","DOI":"10.1016\/S0927-7757(00)00516-1"},{"key":"2","doi-asserted-by":"publisher","unstructured":"Altounyan R.E.C., Howell J.B.L., Treatment of asthma with disodium cromoglycate (FPL 670, \u2018Intal\u2019), Respiration, 26 (2009) 131\u2013140. https:\/\/doi.org\/10.1159\/000192647","DOI":"10.1159\/000192647"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Anzueto A., Miravitlles M., Tiotropium in chronic obstructive pulmonary disease \u2013 a review of clinical development, Respiratory Research, 21 (2020) 199. https:\/\/doi.org\/10.1186\/s12931-020-01407-y","DOI":"10.1186\/s12931-020-01407-y"},{"key":"4","unstructured":"Aptar, 2025, PADA - starter kit for pre-clinical pulmonary research in mice &lt;https:\/\/aptar.com\/&gt; accessed Feb 27 2025."},{"key":"5","doi-asserted-by":"publisher","unstructured":"Baumann J.M., Adam M.S., Wood J.D., Engineering advances in spray drying for pharmaceuticals, Annual Review of Chemical and Biomolecular Engineering, 12 (2021) 217\u2013240. https:\/\/doi.org\/10.1146\/annurev-chembioeng-091720-034106","DOI":"10.1146\/annurev-chembioeng-091720-034106"},{"key":"6","unstructured":"Boehringer Ingelheim 2025 Spiriva<sup>\u00ae<\/sup> HandiHaler<sup>\u00ae<\/sup> (tiotropium bromide inhalation powder) &lt;https:\/\/patient.boehringer-ingelheim.com\/us\/care-connect\/resources\/resources-by-product\/spiriva-handihaler&gt; accessed Feb 25 2025."},{"key":"7","doi-asserted-by":"publisher","unstructured":"Bollmeier S.G., Hartmann A.P., Management of chronic obstructive pulmonary disease: a review focusing on exacerbations, American Journal of Health-System Pharmacy, 77 (2020) 259\u2013268. https:\/\/doi.org\/10.1093\/ajhp\/zxz306","DOI":"10.1093\/ajhp\/zxz306"},{"key":"8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-019-2704-6","volume":"36","author":"M. Braunstein","year":"2019","unstructured":"Braunstein M., Hickey A.J., Ekins S., Why wait? The case for treating tuberculosis with inhaled drugs, Pharmaceutical Research, 36 (2019) 166. https:\/\/doi.org\/10.1007\/s11095-019-2704-6","journal-title":"Pharmaceutical Research","ISSN":"https:\/\/id.crossref.org\/issn\/0724-8741","issn-type":"print"},{"key":"9","doi-asserted-by":"publisher","unstructured":"Brunaugh A.D., Jan S.U., Ferrati S., Smyth H.D.C., Excipient-free pulmonary delivery and macrophage targeting of clofazimine via air jet micronization, Molecular Pharmaceutics, 14 (2017) 4019\u20134031. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00690","DOI":"10.1021\/acs.molpharmaceut.7b00690"},{"key":"10","doi-asserted-by":"crossref","first-page":"e00186","DOI":"10.1128\/aac.00186-22","volume":"66","author":"A.D. Brunaugh","year":"2022","unstructured":"Brunaugh A.D., Walz A., Warnken Z., Pearce C., Munoz Gutierrez J., Koleng John J., Smyth Hugh D.C., Gonzalez-Juarrero M., Respirable clofazimine particles produced by air jet milling technique are efficacious in treatment of BALB\/c Mice with chronic <i>Mycobacterium tuberculosis<\/i> infection, Antimicrobial Agents and Chemotherapy, 66 (2022) e00186-22. https:\/\/doi.org\/10.1128\/aac.00186-22","journal-title":"Antimicrobial Agents and Chemotherapy","ISSN":"https:\/\/id.crossref.org\/issn\/0066-4804","issn-type":"print"},{"key":"11","first-page":"163","volume":"72","author":"R.L. Carr","year":"1965","unstructured":"Carr R.L., Evaluating flow properties of solids, Chemical Engineering, 72 (1965) 163\u2013168.","journal-title":"\u041d\u0430\u0443\u043a\u0430 \u0438 \u0442\u0435\u0445\u043d\u043e\u043b\u043e\u0433\u0438\u0438","ISSN":"https:\/\/id.crossref.org\/issn\/1684-5811","issn-type":"print"},{"key":"12","unstructured":"Century J.F., The impact of intratracheal aerosol technologies on preclinical pulmonary research, Inhalation Magazine, 7 (2013) 18\u201324."},{"key":"13","doi-asserted-by":"crossref","unstructured":"Datta P.K., Liu F., Fischer T., Rappaport J., Qin X., SARS-CoV-2 pandemic and research gaps: understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy, Theranostics, 10 (2020) 7448\u20137464. https:\/\/doi.org\/10.7150\/thno.48076","DOI":"10.7150\/thno.48076"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Devillier P., Humbert M., Boye A., Zachgo W., Jacques L., Nunn C., West S., Nicholls A., Antoun Z., Spinu L., Grouin J.-M., Efficacy and safety of once-daily fluticasone furoate\/vilanterol (FF\/VI) versus twice-daily inhaled corticosteroids\/long-acting \u03b22-agonists (ICS\/LABA) in patients with uncontrolled asthma: an open-label, randomized, controlled trial, Respiratory Medicine, 141 (2018) 111\u2013120. https:\/\/doi.org\/10.1016\/j.rmed.2018.06.009","DOI":"10.1016\/j.rmed.2018.06.009"},{"key":"15","doi-asserted-by":"publisher","unstructured":"Dharmadhikari A.S., Kabadi M., Gerety B., Hickey Anthony J., Fourie P.B., Nardell E., Phase I, Single-Dose, Dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis, Antimicrobial Agents and Chemotherapy, 57 (2013) 2613\u20132619. https:\/\/doi.org\/10.1128\/aac.02346-12","DOI":"10.1128\/AAC.02346-12"},{"key":"16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.14356\/kona.1998007","volume":"16","author":"C.A. Dunbar","year":"1998","unstructured":"Dunbar C.A., Hickey A.J., Holzner P., Dispersion and characterization of pharmaceutical dry powder aerosols, KONA Powder and Particle Journal, 16 (1998) 7\u201345. https:\/\/doi.org\/10.14356\/kona.1998007","journal-title":"KONA Powder and Particle Journal","ISSN":"https:\/\/id.crossref.org\/issn\/0288-4534","issn-type":"print"},{"key":"17","doi-asserted-by":"publisher","unstructured":"Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., Mintzes J., Deaver D., Lotan N., Langer R., Large porous particles for pulmonary drug delivery, Science, 276 (1997) 1868\u20131871. https:\/\/doi.org\/10.1126\/science.276.5320.1868","DOI":"10.1126\/science.276.5320.1868"},{"key":"18","doi-asserted-by":"publisher","unstructured":"Farinha S., S\u00e1 J.V., Lino P.R., Gal\u00e9sio M., Pires J., Rodrigues M.\u00c2., Henriques J., Spray freeze drying of biologics: a review and applications for inhalation delivery, Pharmaceutical Research, 40 (2023) 1115\u20131140. https:\/\/doi.org\/10.1007\/s11095-022-03442-4","DOI":"10.1007\/s11095-022-03442-4"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Farrell A.G., Dadonaite B., Greaney A.J., Eguia R., Loes A.N., Franko N.M., Logue J., Carre\u00f1o J.M., Abbad A., Chu H.Y., Matreyek K.A., Bloom J.D., Receptor-binding domain (RBD) antibodies contribute more to SARS-CoV-2 neutralization when target cells express high levels of ACE2, Viruses, 14 (2022) 2061. https:\/\/doi.org\/10.3390\/v14092061","DOI":"10.3390\/v14092061"},{"key":"20","doi-asserted-by":"publisher","unstructured":"Ferguson G.T., Hickey A.J., Dwivedi S., Cosuspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases, Respiratory Medicine, 134 (2018) 16\u201323. https:\/\/doi.org\/10.1016\/j.rmed.2017.09.012","DOI":"10.1016\/j.rmed.2017.09.012"},{"key":"21","doi-asserted-by":"publisher","unstructured":"Fiegel J., Garcia-Contreras L., Thomas M., VerBerkmoes J., Elbert K., Hickey A., Edwards D., Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin, Pharmaceutical Research, 25 (2008) 805\u2013811. https:\/\/doi.org\/10.1007\/s11095-007-9381-6","DOI":"10.1007\/s11095-007-9381-6"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Foerter-Barth U., Teipel U., Characterization of particles by means of laser light diffraction and dynamic light scattering, in: Massacci P. (Ed.) Developments in Mineral Processing, Elsevier, 2000, pp. C1-1\u2013C1-8. https:\/\/doi.org\/10.1016\/S0167-4528(00)80003-4","DOI":"10.1016\/S0167-4528(00)80003-4"},{"key":"23","unstructured":"FPAN, 2025, Spiriva<sup>\u00ae<\/sup> Handihaler<sup>\u00ae<\/sup> &lt;https:\/\/www.fpanetwork.org\/device\/spiriva-handihaler\/&gt; accessed Feb 25 2025."},{"key":"24","doi-asserted-by":"publisher","unstructured":"Garcia Contreras L., Sung J., Ibrahim M., Elbert K., Edwards D., Hickey A., Pharmacokinetics of inhaled rifampicin porous particles for tuberculosis treatment: insight into rifampicin absorption from the lungs of guinea pigs, Molecular Pharmaceutics, 12 (2015) 2642\u20132650. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00046","DOI":"10.1021\/acs.molpharmaceut.5b00046"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Ge J., Wang R., Ju B., Zhang Q., Sun J., Chen P., Zhang S., Tian Y., Shan S., Cheng L., Zhou B., Song S., Zhao J., Wang H., Shi X., et al.., Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry, Nature Communications, 12 (2021) 250. https:\/\/doi.org\/10.1038\/s41467-020-20501-9","DOI":"10.1038\/s41467-020-20501-9"},{"key":"26","doi-asserted-by":"publisher","unstructured":"Geller D.E., Weers J.G., Heuerding S., Development of an inhaled dry-powder formulation of tobramycin using Pulmosphere<sup>TM<\/sup> technology, Journal of Aerosol Medicine and Pulmonary Drug Delivery, 24 (2011) 175\u2013182. https:\/\/doi.org\/10.1089\/jamp.2010.0855","DOI":"10.1089\/jamp.2010.0855"},{"key":"27","doi-asserted-by":"publisher","unstructured":"Gonda I., Inhalation therapy with recombinant human deoxyribonuclease I, Advanced Drug Delivery Reviews, 19 (1996) 37\u201346. https:\/\/doi.org\/10.1016\/0169-409X(95)00096-P","DOI":"10.1016\/0169-409X(95)00096-P"},{"key":"28","doi-asserted-by":"publisher","unstructured":"Gonzalez-Juarrero M., Lukka P.B., Wagh S., Walz A., Arab J., Pearce C., Ali Z., Ryman J.T., Parmar K., Temrikar Z., Munoz-Gutierrez J., Robertson G.T., Liu J., Lenaerts A.J., Daley C., et al.., Preclinical evaluation of inhalational spectinamide-1599 therapy against tuberculosis, ACS Infectious Diseases, 7 (2021) 2850\u20132863. https:\/\/doi.org\/10.1021\/acsinfecdis.1c00213","DOI":"10.1021\/acsinfecdis.1c00213"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Gordon A., Li B., Witten J., Nguyen H., Anderson D.G., Inhalable Dry powders for lung mRNA delivery, Advanced Healthcare Materials, 13 (2024) 2400509. https:\/\/doi.org\/10.1002\/adhm.202400509","DOI":"10.1002\/adhm.202400509"},{"key":"30","unstructured":"Groth S., Dirksen H., Optimal inhalation procedure for the fenoterol powder inhaler, European Journal of Respiratory Diseases Supplement, 130 (1983) 17\u201324. PMID: 6581057."},{"key":"31","unstructured":"GSK, 2021, Advair Diskus 250\/50 &lt;https:\/\/www.advair.com\/&gt; accessed Feb 25 2025."},{"key":"32","unstructured":"GSK, 2023a, Breo Ellipta (fluticasone furoate 100 mcg and vilanterol 25 mcg inhalation powder) &lt;https:\/\/www.mybreo.com\/&gt; accessed Feb 25 2025."},{"key":"33","unstructured":"GSK, 2023b, Trelegy Ellipta (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder) &lt;https:\/\/gskpro.com\/&gt; accessed Feb 25 2025."},{"key":"34","unstructured":"Hickey A., Montgomery A.B., Aerosolized pentamidine for treatment and prophylaxis of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome, in: Hickey A.J. (Ed.) Pharmaceutical Inhalation Aerosol Technology (2nd ed.), CRC Press, New York, NY, 2004, pp. 415\u2013425, ISBN: 9780429223464. https:\/\/doi.org\/10.1201\/9780203912898"},{"key":"35","doi-asserted-by":"publisher","unstructured":"Hickey A.J., Controlled delivery of inhaled therapeutic agents, Journal of Controlled Release, 190 (2014) 182\u2013188. https:\/\/doi.org\/10.1016\/j.jconrel.2014.05.058","DOI":"10.1016\/j.jconrel.2014.05.058"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Hickey A.J., Pulmonary drug delivery: pharmaceutical chemistry and aerosol technology, in: Wang B.,Hu L., Siahaan T.J. (Eds.), Drug Delivery: Principles and Applications (2nd ed.), John Wiley &amp; Sons, Inc., Hoboken, NJ, 2016, pp. 186\u2013206, ISBN: 9781118833360. https:\/\/doi.org\/10.1002\/9781118833322.ch10","DOI":"10.1002\/9781118833322.ch10"},{"key":"37","doi-asserted-by":"publisher","unstructured":"Hickey A.J., Complexity in pharmaceutical powders for inhalation: a perspective, KONA Powder and Particle Journal, 35 (2018a) 3\u201313. https:\/\/doi.org\/10.14356\/kona.2018007","DOI":"10.14356\/kona.2018007"},{"key":"38","unstructured":"Hickey A.J., Inhaled Pharmaceutical Product Development Perspectives, Elsevier, New York, NY, 2018b, ISBN: 9780128122099."},{"key":"39","doi-asserted-by":"publisher","unstructured":"Hickey A.J., Dry powder inhalers: an overview, Journal of Aerosol Medicine and Pulmonary Drug Delivery, 36 (2023) 316\u2013323. https:\/\/doi.org\/10.1089\/jamp.2023.29104.ajh","DOI":"10.1089\/jamp.2023.29104.ajh"},{"key":"40","unstructured":"Hickey A.J., Overcoming biological and technical challenges to achieve high dose drug delivery to the lungs, Proceedings of Respiratory Drug Delivery 2024, pp. 130\u2013136."},{"key":"41","doi-asserted-by":"publisher","unstructured":"Hickey A.J., Maloney S.E., Kuehl P.J., Phillips J.E., Wolff R.K., Practical considerations in dose extrapolation from animals to humans, Journal of Aerosol Medicine and Pulmonary Drug Delivery, 37 (2024) 77\u201389. https:\/\/doi.org\/10.1089\/jamp.2023.0041","DOI":"10.1089\/jamp.2023.0041"},{"key":"42","doi-asserted-by":"publisher","unstructured":"Hickey A.J., Mansour H.M., Telko M.J., Xu Z., Smyth H.D.C., Mulder T., McLean R., Langridge J., Papadopoulos D., Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics, Journal of Pharmaceutical Sciences, 96 (2007a) 1282\u20131301. https:\/\/doi.org\/10.1002\/jps.20916","DOI":"10.1002\/jps.20916"},{"key":"43","doi-asserted-by":"publisher","unstructured":"Hickey A.J., Mansour H.M., Telko M.J., Xu Z., Smyth H.D.C., Mulder T., McLean R., Langridge J., Papadopoulos D., Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics., Journal of Pharmaceutical Sciences, 96 (2007b) 1302\u20131319. https:\/\/doi.org\/10.1002\/jps.20943","DOI":"10.1002\/jps.20943"},{"key":"44","doi-asserted-by":"publisher","unstructured":"Hickey A.J., Misra A., Fourie P.B., Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis, Journal of Pharmaceutical Sciences, 102 (2013) 3900\u20133907. https:\/\/doi.org\/10.1002\/jps.23705","DOI":"10.1002\/jps.23705"},{"key":"45","unstructured":"Hofmann T., Ufer S., Canisius S., The evolving unmet need for high dose inhaled therapies in orphan lung disease, Proceedings of Respiratory Drug Delivery 2024, pp. 123\u2013129."},{"key":"46","first-page":"63","volume":"8","author":"P. Holzner","year":"1998","unstructured":"Holzner P., Hickey A.J., Schreier H., Liposomal dry powder aerosols for gene and drug delivery to the lung, Journal of Liposome Research, 8 (1998) 63\u201364. https:\/\/doi.org\/10.3109\/08982109809087425","journal-title":"Journal of Liposome Research","ISSN":"https:\/\/id.crossref.org\/issn\/0898-2104","issn-type":"print"},{"key":"47","doi-asserted-by":"publisher","unstructured":"Hoppentocht M., Hagedoorn P., Frijlink H.W., de Boer A.H., Technological and practical challenges of dry powder inhalers and formulations, Advanced Drug Delivery Reviews, 75 (2014) 18\u201331. https:\/\/doi.org\/10.1016\/j.addr.2014.04.004","DOI":"10.1016\/j.addr.2014.04.004"},{"key":"48","doi-asserted-by":"publisher","unstructured":"Hufnagel S., Sahakijpijarn S., Moon C., Cui Z., Williams Iii R.O., The development of thin-film freezing and its application to improve delivery of biologics as dry powder aerosols, KONA Powder and Particle Journal, 39 (2022) 176\u2013192. https:\/\/doi.org\/10.14356\/kona.2022010","DOI":"10.14356\/kona.2022010"},{"key":"49","doi-asserted-by":"publisher","unstructured":"Jager P.D., Bramante T., Luner P.E., Assessment of pharmaceutical powder flowability using shear cell-based methods and application of Jenike\u2019s methodology, Journal of Pharmaceutical Sciences, 104 (2015) 3804\u20133813. https:\/\/doi.org\/10.1002\/jps.24600","DOI":"10.1002\/jps.24600"},{"key":"50","doi-asserted-by":"publisher","unstructured":"Jenike A.W., Quantitative design of mass-flow bins, Powder Technology, 1 (1967) 237\u2013244. https:\/\/doi.org\/10.1016\/0032-5910(67)80042-1","DOI":"10.1016\/0032-5910(67)80042-1"},{"key":"51","doi-asserted-by":"crossref","first-page":"1700433","DOI":"10.1002\/adhm.201700433","volume":"6","author":"R.K. Kankala","year":"2017","unstructured":"Kankala R.K., Zhang Y.S., Wang S.-B., Lee C.-H., Chen A.-Z., Supercritical fluid technology: an emphasis on drug delivery and related biomedical applications, Advanced Healthcare Materials, 6 (2017) 1700433. https:\/\/doi.org\/10.1002\/adhm.201700433","journal-title":"Advanced Healthcare Materials","ISSN":"https:\/\/id.crossref.org\/issn\/2192-2640","issn-type":"print"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Liu S., Wen Y., Shan X., Ma X., Yang C., Cheng X., Zhao Y., Li J., Mi S., Huo H., Li W., Jiang Z., Li Y., Lin J., Miao L., et al.., Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination, Nature Communications, 15 (2024) 9471. https:\/\/doi.org\/10.1038\/s41467-024-53914-x","DOI":"10.1038\/s41467-024-53914-x"},{"key":"53","doi-asserted-by":"publisher","unstructured":"Lopes Dos Santos J.M., Costa H., St\u00e5hl E., Wir\u00e9n J.E., Bricanyl<sup>\u00ae<\/sup> Turbuhaler<sup>\u00ae<\/sup> and Ventolin<sup>\u00ae<\/sup> Rotahaler<sup>\u00ae<\/sup> in exercise-induced asthma in children, Allergy, 46 (1991) 203\u2013205. https:\/\/doi.org\/10.1111\/j.1398-9995.1991.tb00571.x","DOI":"10.1111\/j.1398-9995.1991.tb00571.x"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Mahar R., Chakraborty A., Nainwal N., The influence of carrier type, physical characteristics, and blending techniques on the performance of dry powder inhalers, Journal of Drug Delivery Science and Technology, 76 (2022) 103759. https:\/\/doi.org\/10.1016\/j.jddst.2022.103759","DOI":"10.1016\/j.jddst.2022.103759"},{"key":"55","doi-asserted-by":"crossref","unstructured":"Maloney Norcross S.E., Levin L.P.K., Hickey A.J., Hill D.B., Biopolymeric inhalable dry powders for pulmonary drug delivery, Pharmaceuticals, 17 (2024) 1628. https:\/\/doi.org\/10.3390\/ph17121628","DOI":"10.3390\/ph17121628"},{"key":"56","unstructured":"Maloney S., Graphical abstract, created in BioRender. 2025. https:\/\/BioRender.com\/n21f146"},{"key":"57","doi-asserted-by":"publisher","unstructured":"Maloney S.E., Alshiraihi I.M., Singh A., Stewart I.E., Mariner Gonzalez J., Gonzalez-Juarrero M., Meibohm B., Hickey A.J., Spray dried tigecycline dry powder aerosols for the treatment of nontuberculous mycobacterial pulmonary infections, Tuberculosis, 139 (2023a) 102306. https:\/\/doi.org\/10.1016\/j.tube.2023.102306","DOI":"10.1016\/j.tube.2023.102306"},{"key":"58","doi-asserted-by":"publisher","unstructured":"Maloney S.E., Mecham J.B., Hickey A.J., Performance testing for dry powder inhaler products: towards clinical relevance, KONA Powder and Particle Journal, 40 (2023b) 172\u2013185. https:\/\/doi.org\/10.14356\/kona.2023013","DOI":"10.14356\/kona.2023013"},{"key":"59","doi-asserted-by":"crossref","unstructured":"Maloney S.E., Stewart I.E., Mecham J.B., Gonzalez-Juarrero M., Meibohm B., Hickey A.J., Disposable dosators intended for dry powder delivery to mice, Journal of Visualized Experiments, (2023c) e65756. https:\/\/doi.org\/10.3791\/65756","DOI":"10.3791\/65756"},{"key":"60","doi-asserted-by":"publisher","unstructured":"Maloney S.E., Stewart I.E., Podell B.K., Gary H.E., Mecham J.B., Berube B.J., Baldwin S.L., Coler R.N., Hickey A.J., Preparation strategies of the anti-mycobacterial drug bedaquiline for intrapulmonary routes of administration, Pharmaceuticals, 16 (2023d) 729. https:\/\/doi.org\/10.3390\/ph16050729","DOI":"10.3390\/ph16050729"},{"key":"61","doi-asserted-by":"crossref","unstructured":"Mannino D., Bogart M., Wu B., Germain G., Lalibert\u00e9 F., MacKnight S.D., Jung Y., Stiegler M., Duh M.S., Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: a real-world study, Respiratory Medicine, 197 (2022) 106807. https:\/\/doi.org\/10.1016\/j.rmed.2022.106807","DOI":"10.1016\/j.rmed.2022.106807"},{"key":"62","doi-asserted-by":"crossref","unstructured":"Martins A.C., Oshiro M.Y., Albericio F., de la Torre B.G., Pereira G.J.V., Gonzaga R.V., Trends and perspectives of biological drug approvals by the FDA: a review from 2015 to 2021, Biomedicines, 10 (2022) 2325. https:\/\/doi.org\/10.3390\/biomedicines10092325","DOI":"10.3390\/biomedicines10092325"},{"key":"63","doi-asserted-by":"crossref","unstructured":"McSweeney M.D., Stewart I., Richardson Z., Kang H., Park Y., Kim C., Tiruthani K., Wolf W., Schaefer A., Kumar P., Aurora H., Hutchins J., Cho J.M., Hickey A.J., Lee S.Y., et al., Stable nebulization and muco-trapping properties of regdanvimab\/IN-006 support its development as a potent, dose-saving inhaled therapy for COVID-19, Bioengineering &amp; Translational Medicine, 8 (2023) e10391. https:\/\/doi.org\/10.1002\/btm2.10391","DOI":"10.1002\/btm2.10391"},{"key":"64","doi-asserted-by":"crossref","unstructured":"Miller J.B., Abramson H.A., Ratner B., Aerosol streptomycin treatment of advanced pulmonary tuberculosis in children, American Journal of Diseases of Children, 80 (1950) 207\u2013237. https:\/\/doi.org\/10.1001\/archpedi.1950.04040020216002","DOI":"10.1001\/archpedi.1950.04040020216002"},{"key":"65","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1208\/pt0804110","volume":"8","author":"J. Mitchell","year":"2007","unstructured":"Mitchell J., Newman S., Chan H.-K., In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review, AAPS PharmSciTech, 8 (2007) E1\u2013E12. https:\/\/doi.org\/10.1208\/pt0804110","journal-title":"AAPS PharmSciTech","ISSN":"https:\/\/id.crossref.org\/issn\/1530-9932","issn-type":"print"},{"key":"66","doi-asserted-by":"publisher","unstructured":"Mortensen N.P., Hickey A.J., Targeting inhaled therapy beyond the lungs, Respiration, 88 (2014) 353\u2013364. https:\/\/doi.org\/10.1159\/000367852","DOI":"10.1159\/000367852"},{"key":"67","doi-asserted-by":"publisher","unstructured":"Nair V.V., Smyth H.D.C., Inhalable excipient-free dry powder of tigecycline for the treatment of pulmonary infections, Molecular Pharmaceutics, 20 (2023) 4640\u20134653. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00395","DOI":"10.1021\/acs.molpharmaceut.3c00395"},{"key":"68","doi-asserted-by":"publisher","unstructured":"Nelson H.S., Advair: combination treatment with fluticasone propionate\/salmeterol in the treatment of asthma, Journal of Allergy and Clinical Immunology, 107 (2001) 397\u2013416. https:\/\/doi.org\/10.1067\/mai.2001.112939","DOI":"10.1067\/mai.2001.112939"},{"key":"69","doi-asserted-by":"publisher","unstructured":"O\u2019Hara P., Hickey A.J., Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization, Pharmaceutical Research, 17 (2000) 955\u2013961. https:\/\/doi.org\/10.1023\/A:1007527204887","DOI":"10.1023\/A:1007527204887"},{"key":"70","doi-asserted-by":"publisher","unstructured":"Ogata K., A review: recent progress on evaluation of flowability and floodability of powder, KONA Powder and Particle Journal, 36 (2019) 33\u201349. https:\/\/doi.org\/10.14356\/kona.2019002","DOI":"10.14356\/kona.2019002"},{"key":"71","doi-asserted-by":"crossref","unstructured":"Paczkowska-Walendowska M., Rosiak N., Tykarska E., Michalska K., P\u0142azi\u0144ska A., P\u0142azi\u0144ski W., Szymanowska D., Cielecka-Piontek J., Tedizolid-cyclodextrin system as delayed-release drug delivery with antibacterial activity, International Journal of Molecular Sciences, 22 (2021) 115. https:\/\/doi.org\/10.3390\/ijms22010115","DOI":"10.3390\/ijms22010115"},{"key":"72","doi-asserted-by":"crossref","unstructured":"Pardeshi S.R., Kole E.B., Kapare H.S., Chandankar S.M., Shinde P.J., Boisa G.S., Salgaonkar S.S., Giram P.S., More M.P., Kolimi P., Nyavanandi D., Dyawanapelly S., Junnuthula V., Progress on thin film freezing technology for dry powder inhalation formulations, Pharmaceutics, 14 (2022) 2632. https:\/\/doi.org\/10.3390\/pharmaceutics14122632","DOI":"10.3390\/pharmaceutics14122632"},{"key":"73","doi-asserted-by":"crossref","unstructured":"Patton J.S., Unlocking the opportunity of tight glycaemic control, Diabetes, Obesity and Metabolism, 7 (2005) S5\u2013S8. https:\/\/doi.org\/10.1111\/j.1463-1326.2005.00530.x","DOI":"10.1111\/j.1463-1326.2005.00530.x"},{"key":"74","doi-asserted-by":"publisher","unstructured":"Paul D., Miller M.H., Born J., Samaddar S., Ni H., Avila H., Krishnamurthy V.R., Thirunavukkarasu K., The promising therapeutic potential of oligonucleotides for pulmonary fibrotic diseases, Expert Opinion on Drug Discovery, 18 (2023) 193\u2013206. https:\/\/doi.org\/10.1080\/17460441.2023.2160439","DOI":"10.1080\/17460441.2023.2160439"},{"key":"75","doi-asserted-by":"crossref","unstructured":"Qiu Y., Liao Q., Chow M.Y.T., Lam J.K.W., Intratracheal administration of dry powder formulation in mice, Journal of Visualized Experiments, 161 (2020) e61469. https:\/\/doi.org\/10.3791\/61469","DOI":"10.3791\/61469-v"},{"key":"76","doi-asserted-by":"publisher","unstructured":"Rahimpour Y., Kouhsoltani M., Hamishehkar H., Alternative carriers in dry powder inhaler formulations, Drug Discovery Today, 19 (2014) 618\u2013626. https:\/\/doi.org\/10.1016\/j.drudis.2013.11.013","DOI":"10.1016\/j.drudis.2013.11.013"},{"key":"77","doi-asserted-by":"publisher","unstructured":"Rostamnezhad M., Jafari H., Moradikhah F., Bahrainian S., Faghihi H., Khalvati R., Bafkary R., Vatanara A., Spray freeze-drying for inhalation application: process and formulation variables, Pharmaceutical Development and Technology, 27 (2022) 251\u2013267. https:\/\/doi.org\/10.1080\/10837450.2021.2021941","DOI":"10.1080\/10837450.2021.2021941"},{"key":"78","doi-asserted-by":"crossref","unstructured":"Sanders M., Pulmonary drug delivery: a historical overview, in: Smyth H.D.C., Hickey A.J. (Eds.), Controlled Pulmonary Drug Delivery, CRS\/Springer, New York, NY, 2011, pp. 51\u201373, ISBN: 978-1-4419-9744-9. https:\/\/doi.org\/10.1007\/978-1-4419-9745-6_3","DOI":"10.1007\/978-1-4419-9745-6_3"},{"key":"79","doi-asserted-by":"publisher","unstructured":"Sarode A., Patel P., Vargas-Montoya N., Allawzi A., Zhilin-Roth A., Karmakar S., Boeglin L., Deng H., Karve S., DeRosa F., Inhalable dry powder product (DPP) of mRNA lipid nanoparticles (LNPs) for pulmonary delivery, Drug Delivery and Translational Research, 14 (2024) 360\u2013372. https:\/\/doi.org\/10.1007\/s13346-023-01402-y","DOI":"10.1007\/s13346-023-01402-y"},{"key":"80","unstructured":"Schreier H., Mobley W.C., Concessio N., Hickey A.J., Niven R.W., Formulation and in vitro performance of liposome powder aerosols, STP Pharma Sciences, 4 (1994) 38\u201344."},{"key":"81","doi-asserted-by":"publisher","unstructured":"Schwarz C., Colobreathe<sup>\u00ae<\/sup> for the treatment of cystic fibrosis-associated pulmonary infections, Pulmonary Therapy, 1 (2015) 19\u201330. https:\/\/doi.org\/10.1007\/s41030-015-0007-6","DOI":"10.1007\/s41030-015-0007-6"},{"key":"82","doi-asserted-by":"publisher","unstructured":"Setji T.L., Hong B.D., Feinglos M.N., Technosphere insulin: inhaled prandial insulin, Expert Opinion on Biological Therapy, 16 (2016) 111\u2013117. https:\/\/doi.org\/10.1517\/14712598.2016.1121230","DOI":"10.1517\/14712598.2016.1121230"},{"key":"83","doi-asserted-by":"publisher","unstructured":"Shetty N., Cipolla D., Park H., Zhou Q.T., Physical stability of dry powder inhaler formulations, Expert Opinion on Drug Delivery, 17 (2020) 77\u201396. https:\/\/doi.org\/10.1080\/17425247.2020.1702643","DOI":"10.1080\/17425247.2020.1702643"},{"key":"84","doi-asserted-by":"publisher","unstructured":"Sibum I., Hagedoorn P., de Boer A.H., Frijlink H.W., Grasmeijer F., Challenges for pulmonary delivery of high powder doses, International Journal of Pharmaceutics, 548 (2018) 325\u2013336. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.07.008","DOI":"10.1016\/j.ijpharm.2018.07.008"},{"key":"85","unstructured":"Smyth H.D.C., Patient focused device design for high payload therapies, Proceedings of Respiratory Drug Delivery 2024, pp. 137\u2013144."},{"key":"86","doi-asserted-by":"crossref","unstructured":"Son Y.-J., Miller D.P., Weers J.G., Optimizing spray-dried porous particles for high dose delivery with a portable dry powder inhaler, Pharmaceutics, 13 (2021) 1528. https:\/\/doi.org\/10.3390\/pharmaceutics13091528","DOI":"10.3390\/pharmaceutics13091528"},{"key":"87","doi-asserted-by":"crossref","unstructured":"Stewart I.E., Durham P.G., Sittenauer J.M., Barreda A.P., Stowell G.W., Moody C., Mecham J.B., Simpson C., Daily S., Maloney S.E., Williams M.D., Severynse-Stevens D., Hickey A.J., Optimization and scale up of spray dried CPZEN-45 aerosol powders for inhaled tuberculosis treatment, Pharmaceutical Research, 39 (2022) 3359\u20133370. https:\/\/doi.org\/10.1007\/s11095-022-03393-w","DOI":"10.1007\/s11095-022-03393-w"},{"key":"88","doi-asserted-by":"publisher","unstructured":"Stewart I.E., Lukka P.B., Liu J., Meibohm B., Gonzalez-Juarrero M., Braunstein M.S., Lee R.E., Hickey A.J., Development and characterization of a dry powder formulation for anti-tuberculosis drug spectinamide 1599, Pharmaceutical Research, 36 (2019) 136. https:\/\/doi.org\/10.1007\/s11095-019-2666-8","DOI":"10.1007\/s11095-019-2666-8"},{"key":"89","doi-asserted-by":"publisher","unstructured":"Stribling R., Brunette E., Liggitt D., Gaensler K., Debs R., Aerosol gene therapy in vivo, Proceedings of the National Academy of Sciences, 89 (1992) 11277\u201311281. https:\/\/doi.org\/10.1073\/pnas.89.23.11277","DOI":"10.1073\/pnas.89.23.11277"},{"key":"90","unstructured":"Suarez S., Hickey A., Pharmacokinetic and pharmacodynamic aspects of inhaled therapeutic agents, Medical Applications of Computer Modeling: The Respiratory System WIT Press, Southampton, UK, (2001) 225\u2013304."},{"key":"91","doi-asserted-by":"crossref","unstructured":"Suarez S., O\u2019Hara P., Kazantseva M., Newcomer C.E., Hopfer R., McMurray D.N., Hickey A.J., Airways delivery of rifampicin microparticles for the treatment of tuberculosis, Journal of Antimicrobial Chemotherapy, 48 (2001a) 431\u2013434. https:\/\/doi.org\/10.1093\/jac\/48.3.431","DOI":"10.1093\/jac\/48.3.431"},{"key":"92","doi-asserted-by":"publisher","unstructured":"Suarez S., O\u2019Hara P., Kazantseva M., Newcomer C.E., Hopfer R., McMurray D.N., Hickey A.J., Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model, Pharmaceutical Research, 18 (2001b) 1315\u20131319. https:\/\/doi.org\/10.1023\/A:1013094112861","DOI":"10.1023\/A:1013094112861"},{"key":"93","unstructured":"Sule S., Ambadekar S., Application of dynamic vapour soprtion technique to study dry powder inhalation formulations, American Journal of Chemistry, 10 (2020) 45\u201349. https:\/\/doi.org\/10.5923\/j.chemistry.20201003.02"},{"key":"94","doi-asserted-by":"publisher","unstructured":"Sung J.C., Padilla D.J., Garcia-Contreras L., VerBerkmoes J.L., Durbin D., Peloquin C.A., Elbert K.J., Hickey A.J., Edwards D.A., Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery, Pharmaceutical Research, 26 (2009) 1847\u20131855. https:\/\/doi.org\/10.1007\/s11095-009-9894-2","DOI":"10.1007\/s11095-009-9894-2"},{"key":"95","doi-asserted-by":"publisher","unstructured":"Szefler S.J., Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid, Journal of Allergy and Clinical Immunology, 104 (1999) S175\u2013S183. https:\/\/doi.org\/10.1016\/S0091-6749(99)70059-X","DOI":"10.1016\/S0091-6749(99)70059-X"},{"key":"96","first-page":"1209","volume":"50","author":"M.J. Telko","year":"2005","unstructured":"Telko M.J., Hickey A.J., Dry powder inhaler formulation, Respiratory Care, 50 (2005) 1209\u20131227. https:\/\/doi.org\/10.4187\/respcare.05501209","journal-title":"Respiratory Care","ISSN":"https:\/\/id.crossref.org\/issn\/0020-1324","issn-type":"print"},{"key":"97","unstructured":"TFF Pharmaceuticals Inc., TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs, 2024."},{"key":"98","unstructured":"USP, General Chapter &lt;601&gt; Aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers. Physical tests and determinations, United States Pharmacopeia, 2012."},{"key":"99","unstructured":"USP, General Chapter &lt;1174&gt; Powder flow, United States Pharmacopeia, 2024."},{"key":"100","unstructured":"USP, General Chapter &lt;616&gt; Bulk density of powders, United States Pharmacopeia, 2025."},{"key":"101","doi-asserted-by":"publisher","unstructured":"Vehring R., Pharmaceutical particle engineering via spray drying, Pharmaceutical Research, 25 (2008) 999\u20131022. https:\/\/doi.org\/10.1007\/s11095-007-9475-1","DOI":"10.1007\/s11095-007-9475-1"},{"key":"102","doi-asserted-by":"publisher","unstructured":"Wu X., Li X., Mansour H.M., Surface analytical techniques in solid-state particle characterization for predicting performance in dry powder inhalers, KONA Powder and Particle Journal, 28 (2010) 3\u201318. https:\/\/doi.org\/10.14356\/kona.2010005","DOI":"10.14356\/kona.2010005"},{"key":"103","doi-asserted-by":"publisher","unstructured":"Yang M.-S., Kang J.-H., Kim D.-W., Park C.-W., Recent developments in dry powder inhalation (DPI) formulations for lung-targeted drug delivery, Journal of Pharmaceutical Investigation, 54 (2024) 113\u2013130. https:\/\/doi.org\/10.1007\/s40005-023-00635-w","DOI":"10.1007\/s40005-023-00635-w"},{"key":"104","doi-asserted-by":"crossref","unstructured":"Young E.F., Durham P.G., Perkowski E.F., Malik S., Hickey A.J., Braunstein M., Efficacy of inhaled CPZEN-45 in treating tuberculosis in the guinea pig, Tuberculosis, 135 (2022) 102207. https:\/\/doi.org\/10.1016\/j.tube.2022.102207","DOI":"10.1016\/j.tube.2022.102207"},{"key":"105","doi-asserted-by":"publisher","unstructured":"Zimmermann C.M., Baldassi D., Chan K., Adams N.B.P., Neumann A., Porras-Gonzalez D.L., Wei X., Kneidinger N., Stoleriu M.G., Burgstaller G., Witzigmann D., Luciani P., Merkel O.M., Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery, Journal of Controlled Release, 351 (2022) 137\u2013150. https:\/\/doi.org\/10.1016\/j.jconrel.2022.09.021","DOI":"10.1016\/j.jconrel.2022.09.021"}],"container-title":["KONA Powder and Particle Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kona\/43\/0\/43_2026011\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:07:22Z","timestamp":1772251642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kona\/43\/0\/43_2026011\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":105,"journal-issue":{"issue":"0","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.14356\/kona.2026011","relation":{"references":[{"id-type":"doi","id":"10.50931\/data.kona.31154704","asserted-by":"subject"}]},"ISSN":["0288-4534","2187-5537"],"issn-type":[{"value":"0288-4534","type":"print"},{"value":"2187-5537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"article-number":"2026011"}}